Leading article

Thyroid hormone receptor-beta agonists: new MASLD therapies 

Byrne CD, Targher G, Tilg H. Thyroid hormone receptor-beta agonists: new MASLD therapies on the horizon. Gut 2024; 73: 573-581. doi: 10.1136/gutjnl-2023-330596

Read it here.

Colon

Blood-based colorectal cancer screening in an integrated health system

Coronado G, Jenkins C, Shuster E. et al. Blood-based colorectal cancer screening in an integrated health system: a randomised trial of patient adherence. Gut 2024; 73:622-628. doi: 10.1136/gutjnl-2023-330980.

Read it here.

IBD

Early-life diet and risk of inflammatory bowel disease: a pooled study in two Scandinavian birth cohorts

Guo A, Ludvigsson J, Brantsaeter A, et al. Early-life diet and risk of inflammatory bowel disease: a pooled study in two Scandinavian birth cohorts. Gut 2024; 73: 590-600. doi: 10.1136/gutjnl-2023-330971.

Read it here.

Oesophageal

10-year follow-up results of the European Achalasia Trial: a multicentre randomised controlled trial comparing pneumatic dilation with laparoscopic Heller myotomy

Boeckxstaens G, Elsen S, Belmans A, et al. 10-year follow-up results of the European Achalasia Trial: a multicentre randomised controlled trial comparing pneumatic dilation with laparoscopic Heller myotomy. Gut 2024; 73:582-589. doi: 10.1136/gutjnl-2023-331374. 

Read it here.

Hepatology

Endoscopic variceal ligation versus propranolol for the primary prevention of oesophageal variceal bleeding in patients with hepatocellular carcinoma: an open-label, two-centre, randomised controlled trial

Yang T, Chen W, Hou M, et al. Endoscopic variceal ligation versus propranolol for the primary prevention of oesophageal variceal bleeding in patients with hepatocellular carcinoma: an open-label, two-centre, randomised controlled trial. Gut 2024; 73: 682-690. doi: 10.1136/gutjnl-2023-330419

Read it here.

Pancreas

Protein biomarkers and alternatively methylated cell-free DNA detect early-stage pancreatic cancer 

Ben-Ami R, Wang Q, Zhang J, et al. Protein biomarkers and alternatively methylated cell-free DNA detect early-stage pancreatic cancer. Gut 2024; 73: 639-648. doi: 10.1136/gutjnl-2023-331074

Read it here.

Reviewers

• Dr Keith Pohl, South West Endoscopy Training Academy Leadership Fellow and Gastroenterology Registrar, Torbay and South Devon NHS Foundation Trust, Torquay, UK
• Dr Nurulamin Noor, Clinical Lecturer in Gastroenterology, University of Cambridge and Cambridge University Hospitals, Cambridge, UK
• Dr Gaurav Nigam, NIHR Clinical Research Fellow, University of Oxford and Oxford University Hospitals, Oxford, UK
• Dr Brian Ho, Honorary Clinical Research Fellow and Gastroenterology Registrar, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK 
• Dr Anahita Sharma, Gastroenterology Registrar, Department of Gastroenterology, East Lancashire NHS Hospitals Foundation Trust, Burnley, UK
• Dr Akudo Nwaogu, Gastroenterology Registrar, Department of Gastroenterology, King’s College Hospital NHS Trust, London, UK

BSG GUT Highlights is edited by Dr Philip J Smith, Honorary Consultant Luminal Gastroenterologist, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Mount Vernon, Liverpool, UK. Dr Smith is the Digital and Education Editor of GUT, Deputy Editor of Frontline Gastroenterology and Associate Editor of BMJ Open Gastroenterology.

Funding

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests

None declared.

Provenance and peer review

Not commissioned; internally peer reviewed.